Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 and the Dow Jones Industrial Average DJIA rising 0.

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average ( ^DJI 0.78%) had just a 12.9% return, compared to 23.3% for the S&P 500 ( ^GSPC 1.00%) and 28.6% for the Nasdaq Composite.

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ... Image source: Getty Images. Eli Lilly (NYSE: LLY) is the maker of one of today's most in-demand treatments: weight loss drugs.

Stocks were sharply lower Monday afternoon on concerns about the competitive threat that China poses in the race to develop artificial intelligence.

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select Sector SPDR Fund (XLK) rose more than 2%, following a 4.9% loss on Monday. The Nasdaq Composite surged 2.03% to 19,733.59, following a 3.1% decline a day ago.

In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3% ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same time,

Novo's U.S. and Europe-listed stocks leapt. Shares of rival Eli Lilly (LLY) also rallied. 🔎 Affirm (AFRM): The "buy-now-pay-later" lender secured $750 million in funding from insurer Liberty ...

US PMI data came in more mixed than expected, to little effect. The Dow Jones Industrial Average (DJIA) churned into a soft backpedal on Friday, testing down around 200 points on a slow trading day.

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday